title: Treatment of T-cell large granular lymphocyte leukemia with cyclosporine A: experience in a Chinese single institution.
abstract: T-cell large granular lymphocyte leukemia (T-LGLL) is a rare chronic lymphoproliferative disorder. Available reported data on the treatment regimens of this disease are variable and limited due to low number of patients. We analyzed the efficiency of cyclosporine A (CsA) in the treatment of 28 patients with T-LGLL. The overall response rate (ORR) was 82.1% with hematologic complete remission (HCR) rate of 57.1%. The median time to response (TTR) was 1.8 months and treatment duration with CsA-based regimens was 34.5 months. CsA shows low and manageable toxicity during treatment. Twenty-one patients survived with a median follow-up time of 42.0 months. Our results indicate that CsA is efficacious and safe in the treatment of T-LGLL.
authors: Department of Anemia Therapeutic Center, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Tianjin, PR China.
authors: Xin
authors: X
authors: Zhao
authors: Kang
authors: K
authors: Zhou
authors: Liping
authors: L
authors: Jing
authors: Li
authors: L
authors: Zhang
authors: Guangxin
authors: G
authors: Peng
authors: Yang
authors: Y
authors: Li
authors: Lei
authors: L
authors: Ye
authors: Jianping
authors: J
authors: Li
authors: Huihui
authors: H
authors: Fan
authors: Yuan
authors: Y
authors: Li
authors: Fengkui
authors: F
authors: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D002681:China; D016572:Cyclosporine / Q000008:administration & dosage*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D054066:Leukemia, Large Granular Lymphocytic / Q000188:drug therapy* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine